Atossa Therapeutics, Inc. filed a Current Report on Form 8-K dated September 18, 2026, to make available an updated corporate presentation. The filing details the company's strategy for its lead drug candidate, (Z)-Endoxifen, and outlines its current financial position.
According to the presentation, (Z)-Endoxifen is an oral selective estrogen receptor modulator/degrader (SERM/SERD) designed to treat estrogen-driven diseases. The company states the molecule is delivered as the active metabolite of tamoxifen, bypassing the need for liver metabolism to achieve consistent drug levels and improved tolerability. The drug is reported to be 30x to 100x more potent than the parent drug tamoxifen in vitro.
The company has outlined a dual strategy targeting both oncology and rare diseases. In oncology, the company is advancing (Z)-Endoxifen in breast cancer across neoadjuvant, adjuvant, and metastatic settings. The EVANGELINE Phase 2 trial, which combines (Z)-Endoxifen with goserelin in premenopausal women with ER+/HER2- breast cancer, completed enrollment as of June 30, 2026, with top-line data anticipated in the fourth quarter of 2026.
In rare diseases, the company is pursuing indications for McCune-Albright Syndrome (MAS) and Duchenne Muscular Dystrophy (DMD). The company reports that approximately 800 patients have been dosed with (Z)-Endoxifen to date. Regulatory milestones include Rare Pediatric Disease designations for both MAS and DMD, and an Orphan Drug Designation for DMD. The company anticipates IND clearance for MAS and DMD in the second half of 2026.
Regarding its financial position, the company reported cash and cash equivalents of $26.1 million as of June 30, 2026, with no debt outstanding. The company noted that a registered direct offering in June raised $4.0 million in net proceeds.
